MAPS founder and Executive Director Part of our Year in Review series Nearly 37 years after Rick Doblin founded MAPS in April 1986, the organisation’s second Phase 3 study of MDMA-assisted therapy for PTSD has been completed. Reflecting on this significant journey, Doblin discusses how MAPS, and its PBC subsidiary, are looking to strike a balance between the “diametric values” of public benefit…

Source

Previous articleExpanding ketamine’s horizons for rare neurological disorders
Next articleReunion Neuroscience Appoints Robert Alexander as Chief Medical Officer